ClinicalTrials.gg
RecruitingNCT06526832Updated Jul 30, 2024

A Phase 1 Study of BST02 in Treating Locally Advanced Liver Cancer

A Phase 1 interventional study of BST02 in Locally Advanced Liver Carcinoma, sponsored by BioSyngen Pte Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-30.

Sponsored by BioSyngen Pte Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to investigate the BST02, a tumor infiltrating lymphocyte product, collected from the locally advanced liver cancer subjects

The main questions it aims to answer are:

  1. Safety and tolerability of BST02.
  2. Preliminary efficacy of BST02. Participants will receive a cytoreductive surgery to collect samples for the manufacture of BST02.

Participants will receive BST02 infusion followed by IL-2 infusion. Blood samples will be collected for the analysis of PK and safety.

02

Conditions studied

  • Locally Advanced Liver Carcinoma
03

In context

Lead sponsor

BioSyngen Pte Ltd is the lead sponsor of 8 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of 18-75 years (inclusive);
  2. Patients with or cytologically confirmed advanced liver cancer (including hepatocellular carcinoma and intrahepatic cholangiocarcinoma) staged according to the Barcelona Clinic Liver Cancer (BCLC) Classification Criteria as stage C or stage B unsuitable for local treatment/progression on local treatment; or intrahepatic cholangiocarcinoma that is unresectable, recurrent, or (AJCC 2017, 8th edition, TNM staging of stage IV).
  3. Failure (disease progression or intolerability) after at least guideline-recommended systemic therapy (Atezolizumab + Bevacizumab, Sintilimab + Bevacizumab analogs; Donafenib, Lenvatinib, Sorafenib; FOLFOX4; Gemcitabine in combination with Cis-platin, etc.), refused to receive the standard systemic therapy by the subject, or deemed inappropriate for standard systemic therapy by the investigator;
  4. At least one surgically resectable tumor lesion that has not received radiation therapy or other local treatment within 28 days which will be used to prepare BST02 cells;
  5. At least one in line with the definition of criteria after TIL sampling surgery. If the target lesion is intrahepatic, arterial phase enhancement imaging is required;
  6. (ECOG) score≤1;
  7. score for hepatic cirrhosis ≤7;
  8. Expected survival time≥3 months;
  9. Adequate organ and bone marrow functions, as defined below, at the time of assessment during the screening and preparation period (within 14 days prior to TIL sampling):

    Hematology: (ANC)≥1.5×109/L, Blood Count (PLT)≥90×109/L, (HGB)≥80 g/L (no transfusion or erythropoietin treatment within 14 days); Hepatic function: (ALT) and Aspartate Aminotransferase (AST) levels≤5 × (ULN); Serum Total (TBil) ≤ 1.5×ULN; if Gilbert's syndrome is diagnosed: TBil ≤ 3×ULN; Coagulation function: (APTT) ≤ 1.5×ULN, while International Normalized Ratio (INR), Prothrombin Time (PT) ≤ 1.5×ULN; Renal function: Serum creatinine (Cr)≤1.5×ULN or (Ccr) ≥ 60mL/min (Cockcroft-Gault formula); Cardiac function test: (LVEF)≥50% by echocardiography; arrhythmia with no need for treatment, Fridericia correction formulas (QTcF)≤470 ms (QTcF is calculated using the Fridericia formula, i.e., QTcF = QT/(RR\^0.33), RR is the standardized heart rate value, RR=60/heart rate; if the results of the first test are abnormal, the test can be repeated twice at an interval of at least 5 minutes and the comprehensive result/mean value should be considered to determine the eligibility); Lung function: Percentage of to the predicted value (FEV1%) ≥ 60%;

  10. Prior treatment-induced adverse reactions have recovered to ≤ grade 1 according to the (CTCAE) 5.0 (except for toxicities such as alopecia, grade 2 or less peripheral neurotoxicity, and other toxicities that do not pose a safety risk as determined by the investigator) prior to TIL sampling;
  11. Subjects agree to use effective from the time of signing the form until 6 months after infusion of BST02 cells (non-drug measures for contraception must be taken);
  12. Subjects should fully understand the trial and voluntarily sign the informed consent form, and be able to comply with the visits and related procedures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women;
  2. Subjects with a prior history of severe allergy and to the drugs including, but not limited to, cyclophosphamide, fludarabine, IL-2, and the components of BST02;
  3. Subjects with prior or current history of hepatic encephalopathy; patients with known central nervous system uncontrolled by other treatment or untreated; with exception of patients who have stabilized their symptoms after treatment, and discontinued the treatment of and anticonvulsant medications ≥4 weeks prior to lymphodepletion preconditioning;
  4. Presence of ascites, defined as: Positive signs of ascites on physical examination or ascites that needs to be controlled with interventional therapy (only those with ascites on imaging without intervention may be included); (5) The Indocyanine Green retention test after 15 min (ICG-R15) is ≥30%;

(6) History of organ transplantation, hematopoietic stem cell transplantation; (7) Other serious medical conditions that may limit the subject's participation in this trial, including but not limited to: Hypertension that is uncontrolled by medication (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at rest after taking medication); Uncontrolled diabetes: Fasting blood glucose levels remain above 1 mmol/L after standardized treatment with insulin; Unstable cardiovascular diseases: Uncontrolled congestive cardiac failure, infarct myocardial or unstable arrhythmia or unstable arrhythmia within the last 6 months, percutaneous coronary interventional procedure, acute coronary syndromes, coronary artery bypass transplant; cerebrovascular accident, , cerebral embolism, deep vein thrombosis, etc.; Uncontrolled respiratory system disorder: Pulmonary embolism, , interstitial lung disease, etc.; Active, diseases requiring systemic therapy during the period of the study: Subjects with eczema, vitiligo, psoriasis, alopecia, or Graves's disease who do not require systemic treatment within the last 2 years, other autoimmune disorders that are not expected to recur, and subjects with type I diabetes mellitus who require only insulin replacement therapy may be enrolled; Active infection or active tuberculosis infection with a need for systemic therapy; Mental illness, except for mild depression, and other mild conditions; (8) Patients who are -positive, or positive for syphilis spirochete antibodies; Patients with active or C are required to adopt antiviral therapy during the whole study. Active hepatitis B is defined as positive hepatitis B core antibody (HBcAb) or hepatitis B surface antigen (HBsAg) and HBV-DNA >2000 IU/ml. Active is defined as HCV RNA above the lower limit of detection; (9) Subjects have taken any drugs, such as corticosteroids, within 4 weeks prior to TIL sampling or had combined diseases needing application of immunosuppressive medications for the duration of the trial as judged by the investigator. However, physiologic doses of glucocorticoids (i.e., a maximum dose of 15 mg/day for prednisone or an equivalent dose of other glucocorticoids) are permitted, and inhalational, intranasal, topical, or prophylaxis use of corticosteroids are allowed against contrast allergy; (10) Subjects who have received / PD-L1 monoclonal antibody treatment within 4 weeks prior to lymphodepletion preconditioning , or undergone local treatments such as surgery (except BST02 sampling surgery), interventional therapy, radiotherapy, ablation, or systemic therapy against liver cancer (including those who participated in other clinical trials of drug therapy; metabolism of drugs with 5 half-lives of less than 4 weeks, whichever is shorter); or immunotherapy such as thymopeptide, interferon, or any traditional Chinese medicine used for tumor control within 1 week prior to lymphodepletion preconditioning ; (11) Subjects who have received a within 3 months prior to screening or planned to receive a live vaccine during the trial; (12) Subjects who have undergone major surgery within 4 weeks prior to screening or planned to receive surgery during the trial period (except for TIL sampling surgery); (13) Patients with surgical complications or delayed wound healing prior to lymphodepletion preconditioning who, in the judgment of the investigator, will be at increased risk for lymphodepletion, TIL therapy, IL-2 therapy, or infection; (14) Subjects who have diagnosed as combined other primary malignant neoplasm within 5 years prior to screening, excluding radically treated basal cell carcinoma of skin, squamous cell carcinoma of skin, and/or radically resected carcinoma in situ; (15) Subjects who have received cell therapy products 6 months prior to lymphodepletion preconditioning; (16) Subjects with known alcoholism, drug or substance abuse, and others who, in the opinion of the investigator, are not suitable for participation in this trial.

Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    BST02

    Patients who receive BST02 infusion.

    Biological: BST02

Interventions

  • BiologicalBST02

    BST02 is a tumor infiltrating lymphocyte product manufactured from the sample collected in the patient's tumor lesion.

06

What researchers measure

Primary outcomes

  1. Occurence and incidence of adverse event and severe adverse events.

    The occurrence and incidence (%) of Adverse Events (AEs) as well as Severe Adverse Events (SAEs) after infusion of BST02 for subjects in each dosing group

    Time frame: From the infusion (D0) to D28

  2. Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity (DLT)

    The highest dose which the patients can tolerate, and the occurence of DLT events.

    Time frame: From the infusion (D0) to D28

Secondary outcomes

  1. Tumor response and survival.

    Including following outcomes: Objective Response Rate (ORR), Disease Control Rate (DCR), Time to Response (TTR), Duration of Response (DOR), Progression-Free Survival (PFS), Overall Survival (OS). The tumor responses are judged according to mRECIST criteria.

    Time frame: From the infusion (D0) to D672 (2 years)

  2. PK parameter collection

    PK testing indicator for BST02: Peripheral blood CXCR3+CD8+ T-lymphocyte count.

    Time frame: From before infusion (D-2) to D28

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jul 2025, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Jul 30, 2024
StartActual
Jul 4, 2024
Primary completionEst.
Jul 3, 2025
CompletionEst.
Dec 3, 2025
Last update
Jul 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06526832
Lead sponsor
BioSyngen Pte Ltd
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Jul 4, 2024
Primary completion
Jul 3, 2025 (estimated)
Completion
Dec 3, 2025 (estimated)
Last update
Jul 30, 2024

Study contacts

Yaojun Zhang, Doctor
Contact
zhangyuj@sysucc.org.cn
+8613719433968
Yaojun Zhang, Doctor
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion